Five Prime Therapeutics Inc
Afucosylated Anti-FGFR2IIIB Antibodies
Last updated:
Abstract:
The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
Status:
Application
Type:
Utility
Filling date:
17 Dec 2021
Issue date:
2 Jun 2022